Clenbuterol and salbutamol in the symptomatic treatment of patients with reversible airways obstruction

In a single-blind, partially randomized, crossover study, 48 patients with reversible airways obstruction were treated with 4 mg salbutamol 3-times daily, 20 micrograms clenbuterol twice daily and 40 micrograms clenbuterol twice daily, each regimen being given for 2 weeks. With all treatments there...

Description complète

Détails bibliographiques
Publié dans:Interim guidelines for the control of infections with Vero cytotoxin producing Escherichia coli (VTEC). Subcommittee of the PHLS Working Group on Vero cytotoxin producing Escherichia coli (VTEC). - 1995. - 3(1983), 7 vom: 15., Seite 492-5
Auteur principal: Jaffé, G (Auteur)
Autres auteurs: Grimshaw, J J
Format: Article
Langue:English
Publié: 1983
Accès à la collection:Interim guidelines for the control of infections with Vero cytotoxin producing Escherichia coli (VTEC). Subcommittee of the PHLS Working Group on Vero cytotoxin producing Escherichia coli (VTEC)
Sujets:Clinical Trial Comparative Study Journal Article Randomized Controlled Trial Ethanolamines Albuterol QF8SVZ843E Clenbuterol XTZ6AXU7KN
Description
Résumé:In a single-blind, partially randomized, crossover study, 48 patients with reversible airways obstruction were treated with 4 mg salbutamol 3-times daily, 20 micrograms clenbuterol twice daily and 40 micrograms clenbuterol twice daily, each regimen being given for 2 weeks. With all treatments there was an improvement in lung function, as indicated by daily monitoring of PEFR and subjective assessment of breathing, and there were no significant differences between them. Side-effects were few. It is considered, therefore, that twice daily regimens of clenbuterol can be as effective as salbutamol given 3-times daily and this may help to improve patient compliance
Description:Date Completed 30.03.1984
Date Revised 21.11.2013
published: Print
Citation Status MEDLINE